FDA delays decision on Pfizer, Bristol-Myers drug

TRENTON, N.J. (AP) — Shares of Pfizer Inc. and Bristol-Myers Squibb Co. fell Monday after federal regulators unexpectedly delayed for a second time a decision on whether to approve the companies’ highly touted experimental anticlotting drug Eliquis.

Some analysts see Eliquis as better than two new clot-preventing pills that beat it to market, but the latest delay means a U.S. launch of Eliquis likely won’t happen until next year.

The Food and Drug Administration said it wants more information on “data management and verification” from a huge international study called ARISTOTLE that examined how well Eliquis prevented strokes in patients with an irregular heartbeat called atrial fibrillation, the drugmakers said Monday.

Comments

Use the comment form below to begin a discussion about this content.

Please review our Policies and Procedures before registering or commenting

News Tribune - comments